October 26, 2022, InDex Pharmaceuticals Holding AB (publ) announced the composition of the Nomination Committee for the 2023 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2023 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board. The Nomination Committee for the 2023 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: Karl Tobieson, appointed by Linc; Ivo Staijen, appointed by HBM Healthcare Investments; Jan Särlvik, appointed by Fjärde AP-fonden; Björn Wasing, appointed SEB-Stiftelsen and S-E-Bankens Utvecklingsstiftelse and Wenche Rolfsen, Chairman of the Board (convener).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.54 SEK | +2.27% | +6.30% | +110.94% |
May. 21 | Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... | |
May. 21 | InDex Pharmaceuticals to Buy Flerie Invest Under Reverse Merger Plan | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+110.94% | 26.7M | |
+42.21% | 739B | |
+32.34% | 598B | |
-5.87% | 353B | |
+17.45% | 318B | |
+3.45% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+5.83% | 164B |
- Stock Market
- Equities
- INDEX Stock
- News InDex Pharmaceuticals Holding AB
- InDex Pharmaceuticals Holding AB Announces Appointment of Nomination Committee for the 2023 Annual General Meeting